Anti-AFF2 Antibody, clone 1G13 ZooMAb^® Rabbit Monoclonal

200

rabbit

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

1G13, recombinant monoclonal

recombinant, expressed in HEK 293 cells

ZooMAb^® learn more

lyophilized

calculated mol wt 144.77 kDa
observed mol wt ~175 kDa

using Protein A

mouse

human

antibody small pack of 25 μL

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

recombinant expression
Learn more about Antibody Enhanced Validation

affinity binding assay: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

IgG

C-terminal half

NP_002016

P51816

ambient

2-8℃

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1G13 is a Rabbit recombinant monoclonal antibody that specifically detects AF4/FMR2 family member 2 (AFF2). It targets an epitope within 160 amino acids from the C-terminal half.

His-tagged recombinant fragment corresponding to 160 amino acids from the C-terminal half of human AF4/FMR2 family member 2 (AFF2).

Quality Control Testing

Evaluated by Western Blotting in Neuro2A cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected AFF2 in Neuro2A cell lysate.

Tested applications

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected AFF2 in mouse brain tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound human recombinant AFF2 with a KD of 8.6 x 10-9 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

AF4/FMR2 family member 2 (UniProt: P51816; also known as Fragile X E mental retardation syndrome protein, Fragile X mental retardation 2 protein, FMR2P, Protein FMR-2, Protein Ox19) is encoded by the AFF2 (also known as FMR2, OX19) gene (Gene ID: 2334) in human. In mammals four different homologs of Drosophila Lilli protein have been described and are named as AFF1, AFF2, AFF3, and AFF4. AFF1 and 4 are part of super elongation complex (SEC) and are required to release polymerase II. AFF2 and 3 are key subunits of the SEC-like complexes SEC-L2 and SEC-L3, respectively. They are required for transcription elongation in some genes. AFF2 is RNA-binding protein that is involved in alternative splicing regulation through an interaction with G-quartet RNA structure. It associates with mRNA via one of the three RNA-binding domains. AFF2 is mainly expressed in the brain and is most abundant in hippocampus and amygdala. Some expression is also observed in placenta and lung. It localizes with splicing factor SC35 in nuclear speckles where splicing factors are concentrated, assembled, and modified. It is reported to regulates the transcription and toxicity of expanded GGGGCC (G4C2) repeat-containing C9ORF72 allele in Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). CRISPR-Cas9-mediated loss of AFF2 is shown to reduce levels of C9ORF72 RNA, RNA foci, and DPR proteins in neurons derived from iPSCs of patients with C9ORF72-ALS/FTD. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Yuva-Aydemir, Y., et al. (2019). Nat. Commun. 10; 10, Article 5466; Sidorov, MS., et al., (2013). Mol. Brain. 6; Article 15; Melko, M., and Bardoni, B. (2010). Biochemie. 92; 919-926).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

13 - Non Combustible Solids

WGK 1